Peak Retirement Planning Inc. Buys New Position in Exelixis, Inc. $EXEL

Peak Retirement Planning Inc. bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 56,475 shares of the biotechnology company’s stock, valued at approximately $2,332,000.

Other institutional investors have also recently made changes to their positions in the company. Buck Wealth Strategies LLC raised its position in shares of Exelixis by 86.8% during the 3rd quarter. Buck Wealth Strategies LLC now owns 22,353 shares of the biotechnology company’s stock valued at $923,000 after buying an additional 10,389 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Exelixis by 179.7% in the third quarter. Jones Financial Companies Lllp now owns 9,477 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 6,089 shares during the last quarter. State of Wyoming increased its stake in Exelixis by 17.0% in the third quarter. State of Wyoming now owns 13,563 shares of the biotechnology company’s stock valued at $560,000 after acquiring an additional 1,972 shares during the last quarter. TFB Advisors LLC purchased a new stake in Exelixis during the third quarter valued at about $627,000. Finally, Lingohr Asset Management GmbH lifted its stake in Exelixis by 1,258.9% during the third quarter. Lingohr Asset Management GmbH now owns 284,022 shares of the biotechnology company’s stock worth $11,730,000 after purchasing an additional 263,121 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In related news, Director Mary C. Beckerle sold 24,622 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director owned 21,380 shares in the company, valued at $896,463.40. This represents a 53.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 34,187 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 245,235 shares of company stock worth $10,490,600. 2.82% of the stock is currently owned by company insiders.

Exelixis Stock Up 3.5%

Shares of EXEL opened at $42.81 on Tuesday. The stock has a market capitalization of $11.48 billion, a P/E ratio of 18.06, a PEG ratio of 0.75 and a beta of 0.40. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62. The firm has a fifty day simple moving average of $43.77 and a two-hundred day simple moving average of $41.00.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.47 earnings per share. Sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EXEL. Citigroup cut Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. Oppenheimer reiterated a “market perform” rating and set a $36.00 price target on shares of Exelixis in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research note on Tuesday, October 21st. Finally, Stifel Nicolaus set a $43.00 target price on shares of Exelixis in a research report on Wednesday, November 5th. Eleven investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $46.00.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.